Return
Decrease in oceanic crustal thickness since the breakup of Pangaea
DOI:10.1038/NGEO2849.png)
Abstract
En 中文
Earth's mantle has cooled by 6-11 degrees C every 100 million years since the Archaean, 2.5 billion years ago. In more recent times, the surface heat loss that led to this temperature drop may have been enhanced by plate-tectonic processes, such as continental breakup, the continuous creation of oceanic lithosphere at mid-ocean ridges and subduction at deep-sea trenches. Here we use a compilation of marine seismic refraction data from ocean basins globally to analyse changes in the thickness of oceanic crust over time. We find that oceanic crust formed in the mid-Jurassic, about 170 million years ago, is 1.7 km thicker on average than crust produced along the present-day mid-ocean ridge system. If a higher mantle temperature is the cause of thicker Jurassic ocean crust, the upper mantle may have cooled by 15-20 degrees C per 100 million years over this time period. The difference between this and the long-term mantle cooling rate indeed suggests that modern plate tectonics coincide with greater mantle heat loss. We also find that the increase of ocean crustal thickness with plate age is stronger in the Indian and Atlantic oceans compared with the Pacific Ocean. This observation supports the idea that upper mantle temperature in the Jurassic was higher in the wake of the fragmented supercontinent Pangaea due to the effect of continental insulation.
Keywords:
MID-ATLANTIC RIDGE
EAST PACIFIC RISE
SEISMIC STRUCTURE BENEATH
CASCADIA SUBDUCTION ZONE
ONTONG JAVA PLATEAU
KANE FRACTURE-ZONE
WIDE-ANGLE
CONTINENTAL-MARGIN
DEEP-STRUCTURE
UPPER-MANTLE
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
16.1
Papers:
4.7K
Citations:
4.1W
Organization
Cited Papers
Age of the Laschamp excursion determined by U-Th dating of a speleothem geomagnetic record from North America
Geology
IF0
MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis
Blood
IF0

